CGTX

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Cognition Therapeutics (CGTX – Research Report) today and set a price target of $15.00. The company's shares closed last Thursday at $3.60. According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 21.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cognition Therapeutics with a $15.00 average price target.
https://www.tipranks.com/news/blurbs/cognition-therapeutics-cgtx-receives-a-buy-from-b-riley-financial?utm_source=advfn.com&utm_medium=referral